GlassScriptPhysician profile
Alan W Lyne
NPI 1083707087
$2,609.30
in general payments reported to CMS, 2019-2025
15 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.64 · 2021: $794 · 2022: $384 · 2023: $618 · 2024: $349 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,171.00 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $476.40 | 2021-2024 | Rybelsus, Ozempic, Saxenda |
| Abbott Laboratories | $246.08 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $217.22 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| Amgen INC. | $96.34 | 2024-2025 | Repatha, Otezla, Repatha |
| Grt US Holding, INC. | $54.77 | 2022 | |
| Medtronic, INC. | $37.47 | 2023 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $32.72 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.90 | 2023 | |
| Bioventus LLC | $22.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.30 | 2022 | |
| Redhill Biopharma INC. | $18.58 | 2021 | |
| Dexcom, INC. | $18.57 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $17.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.